Journal Article Neuroprotective effects of VCP modulators in mouse models of glaucoma

Nakano, Noriko  ,  Ikeda, Hanako Ohashi  ,  Hasegawa, Tomoko  ,  Muraoka, Yuki  ,  Iwai, Sachiko  ,  Tsuruyama, Tatsuaki  ,  Nakano, Masaki  ,  Fuchigami, Tomohiro  ,  Shudo, Toshiyuki  ,  Kakizuka, Akira  ,  Yoshimura, Nagahisa

2 ( 4 ) 2016-04 , Elsevier Ltd
緑内障の進行を抑制、マウスで成功-新規の化合物を用いた難治性眼疾患の進行抑制に期待-. 京都大学プレスリリース. 2016-04-22.
Glaucoma is a major cause of adult blindness due to gradual death of retinal ganglion cells. Currently, no therapeutics are available for the protection of these cells from the cell death. We have recently succeeded in synthesizing novel compounds, KUSs (Kyoto University Substances), which can reduce cellular ATP consumption by specifically inhibiting the ATPase activities of VCP, a major ATPase in the cell, and we have shown that KUSs could mitigate the disease progression of rd10, a mouse model of retinitis pigmentosa, without any apparent side effects. Here we show that KUSs (e.g. KUS121 and KUS187) can prevent antimycin- and oligomycin-induced ATP depletion, endoplasmic reticulum (ER) stress, and cell death in neuronally differentiated PC12 cells. Furthermore, KUSs manifest significant efficacies on several mouse models of glaucoma. KUS administration prevented or mitigated ER stress and subsequent apoptotic cell death of retinal ganglion cells in an acute injury mouse model of retinal ganglion cell loss, which was induced with N-methyl-D-aspartate. In a mouse model of glaucoma with high intraocular pressure, KUSs prevented the typical glaucoma pathologies, i.e. enlargement of optic disc cupping and thinning of the retinal nerve fiber layer. KUSs also preserved visual functions in GLAST knockout mice, a mouse model for chronic retinal ganglion cell loss. We propose "ATP maintenance" via inhibition of ATPase activities of VCP as a promising new neuroprotective strategy for currently incurable eye diseases, such as glaucoma.

Number of accesses :  

Other information